North Africa Non-Invasive Prenatal Testing Market, By Application (Trisomy, Microdeletion Syndrome, Sex Chromosome Abnormalities, Others), By End User (Hospitals, Diagnostic Centers & Independent Laboratories), By Geography (North Africa)

North Africa Non-Invasive Prenatal Testing Market is estimated to be valued at USD 4,259 Mn in 2026 and is expected to reach USD 7,636 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.7% from 2026 to 2033.

Noninvasive prenatal testing (NIPT) is also known as noninvasive prenatal screening (NIPS). It is a procedure used to determine the chromosomal abnormalities or disorders of the fetus which generally occur due to missing or an extra copy (aneuploidy) of a chromosome. NIPT examines small DNA fragments which are circulating in the blood of pregnant woman. These small fragments are freely floating and hence are called cell-free DNA. NIPT is carried out for the detection of trisomy 18, trisomy 13, Down syndrome, and missing or extra copies of X and Y chromosomes. NIPT is found to be useful during the COVID-19 pandemic situation to avoid the risk of infection. The potential to isolate fetal DNA and fetal cells from maternal blood during pregnancy has revealed exciting opportunities for upgraded noninvasive prenatal testing (NIPT).

Market Dynamics

The strong focus of key players on entering the North African market, and increasing awareness about the adoption of non-invasive prenatal testing are the major factors that are expected to drive the growth of North Africa non-invasive prenatal testing market over the forecast period.

For instance, according to the data published by National Library of Medicine in May 2020, twenty five studies in 9 sub-Saharan African countries manifested that the prevalence of birth defects was 20.40 per 1,000 births.

Moreover, in March 2019, Yourgene Health Plc, an international molecular diagnostics group, arranged an event in Egypt to increase the awareness of IONA test, a non-invasive prenatal DNA test performed for Down syndrome.

Key features of the study

• This report provides an in-depth analysis of North Africa non-invasive prenatal testing market, market size (USD Mn), and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in North Africa non-invasive prenatal testing market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Illumina, Inc., Eurofins Scientific, PerkinElmer, Inc., F. Hoffmann-La Roche AG, Natera, Inc., Yourgene Health Plc, Laboratory Corporation of America Holdings (LabCorp), BGI Group, Quest Diagnostics Incorporated
• Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• North Africa non-invasive prenatal testing market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the

Market Segmentation

• By Application
  • Trisomy
  • Microdeletion Syndrome
  • Sex Chromosome Abnormalities
  • Others
• By End User
  • Hospitals
  • Diagnostic Centers & Independent Laboratories
• By Countries
  • Egypt
  • Algeria
  • Morocco
  • Rest of North Africa
• Key Players
  • Illumina, Inc.
  • Eurofins Scientific
  • PerkinElmer, Inc.
  • Hoffmann-La Roche AG
  • Natera, Inc.
  • Yourgene Health Plc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • BGI Group
  • Quest Diagnostics Incorporated.